港股異動 | 復宏漢霖漲近6% 注射液HLX04-O於中國境內完成首例患者給藥
格隆匯11月17日丨復宏漢霖(2696.HK)現漲5.98%,報30.15港元,總市值164億港元,股價創近3個月新高。復宏漢霖11月10日公佈,近日,重組抗VEGF人源化單克隆抗體注射液HLX04-O於中國內地(不包括中國港澳台地區,下同)用於濕性年齡相關性黃斑變性(wAMD)治療的3期臨牀研究完成首例患者給藥。本次研究是一項在濕性年齡相關性黃斑變性(wAMD)患者中開展的多中心、隨機、雙盲、陽性對照的3期臨牀研究,旨在比較HLX04-O與雷珠單抗的有效性和安全性。合格的受試者將以1:1的比例隨機分為兩組,分別接受每四周玻璃體內注射HLX04-O(1.25mg)或雷珠單抗(0.5mg),持續一年。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.